PO.CL01.12 · 临床研究
空间转录组学识别髓外多发性骨髓瘤中抑制性T细胞排斥的肿瘤微环境
Spatial transcriptomics identifies a suppressive T-cell excluded tumour microenvironment in extramedullary multiple myeloma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:多发性骨髓瘤(MM)中的髓外病变(EMD)因侵袭性疾病动力学和治疗耐药而与不良预后相关。局限于骨髓(BM)的MM高度依赖BM微环境生存,据推测这促成了耐药性。在EMD中,其生物学特别是肿瘤微环境(TME)的作用尚不清楚。
方法:使用10x Xenium In Situ Prime 5K分析了来自8例血源性EMD患者的8份活检组织。后续分析采用了近期描述的高分辨率ProSeg细胞分割算法。
结果:共纳入来自8个样本的500,102个细胞。EMD中的浆细胞(PC)维持PC转录组,表达XBP1、IRF4和PRDM1,而无PAX5、FOXP1的显著表达。降维后,与局限于BM的MM类似,PC聚类主要由患者间变异性驱动。对TME进行了评估。数量最多的免疫细胞是巨噬细胞,特别是具有免疫抑制性'M2'表型的巨噬细胞,通过CD163和MRC1等标志物的表达得以证明。浸润的CD8+ T细胞共表达细胞毒性和耗竭基因。癌症相关成纤维细胞是TME中最常见的非免疫细胞。进行了空间分析,识别出复现性微环境:免疫抑制(IS)、免疫排斥(IE)和免疫允许(IP)。以巨噬细胞、成纤维细胞和内皮细胞为特征的IS龛富集免疫细胞和更具增殖性的PC亚群。大部分肿瘤(>70%)构成IE龛,PC占比非常高(>90%细胞),T细胞占比最低。T细胞增多和干扰素反应性巨噬细胞增多的较罕见区域,推测为IP区域,存在于两个样本中。
预测的细胞-细胞相互作用识别出一个复杂的双向网络。PC通过包括TGFB1/3、PGE2和THBS1在内的信号与TME相互作用明显,被预测驱动抑制性巨噬细胞表型和纤维化细胞外基质。相反,TME中表达APRIL和BAFF的巨噬细胞被预测通过包括BCMA、CXCR4和CD38在内的经典配体促进PC存活。因此,TME中抑制性髓系细胞与PC之间的这种双向信号传导据推测直接促进骨髓瘤生长,同时限制抗骨髓瘤免疫。抑制性和排斥性龛存在于所有样本中,提示其在EMD生物学中具有重要作用。
结论:我们的发现为MM EMD的空间组织提供了新见解,并识别出在TME内T细胞排斥背景下显著的抑制性巨噬细胞富集龛,以及PC中的增殖性信号网络,这些代表了新的临床可干预靶点。
查看英文原文 English abstract
Introduction: Extramedullary disease (EMD) in multiple myeloma (MM) is associated with poor prognosis due to aggressive disease kinetics and therapy resistance. Bone marrow (BM) restricted MM is highly dependent on the BM microenvironment for survival, putatively contributing to drug-resistance. In EMD, the biology and particularly the role of the tumor microenvironment (TME) is unknown.
Methods: Eight biopsies from 8 patients with hematogenous EMD were analyzed using 10x Xenium In Situ Prime 5K. Subsequent analysis utilized the recently described high resolution ProSeg cell segmentation algorithm.
Results: A total of 500,102 cells from 8 samples were included. Plasma cells (PC) in EMD maintain a PC transcriptome with expression of XBP1 , IRF4 and PRDM1 without significant expression of PAX5 , FOXP1 . After dimensionality reduction, like BM-restricted MM, PC clustering was driven primarily by inter-patient variability. The TME was assessed. The most numerous immune cells were macrophages, specifically those with an immune-suppressive ‘M2' phenotype, demonstrated by expression of markers such as CD163 and MRC1 . Infiltrating CD8+ T-cells co-expressed cytotoxicity and exhaustion genes. Cancer associated fibroblasts were the most common non-immune cell in the TME. Spatial analysis was performed with recurrent microenvironments identified: immune suppressed (IS), immune excluded (IE) and immune permissive (IP). The IS niches, characterised by macrophages, fibroblasts and endothelial cells, were enriched for immune cells and more proliferative PC subsets. The bulk of tumors (>70%) comprised the IE niche, with a very high proportion of PC (>90% cells) with the lowest proportion of T-cells. Rarer areas with increased T-cells and interferon-reactive macrophages, presumed IP regions, were present in two samples.
Predicted cell-cell interactions identified a complex, bidirectional network. PC interactions with the TME via signals including TGFB1/3 , PGE2 and THBS1 were evident, predicted to drive a suppressive macrophage phenotype and a fibrotic extracellular matrix. Conversely, macrophages in the TME expressing APRIL and BAFF are predicted to promote PC survival via canonical ligands including BCMA, CXCR4 and CD38 . This bidirectional signalling between suppressive myeloid cells in the TME and PC thus putatively promote myeloma growth directly whilst concurrently constraining anti-myeloma immunity. The presence of the suppressive and excluded niches in all samples suggests an important role in EMD biology.
Conclusions: Our findings provide new insights into the spatial organisation of MM EMD and identify prominent suppressive macrophage rich niches in the context of T cell exclusion within the TME, together with proliferative signalling networks in PC, that represent new clinically tractable targets.
利益披露 Disclosure
N. E. Bingham, None..
J. R. Boiko, None..
D. C. Jones, None..
D. Wong, None..
T. Khong, None..
S. Mithraprabhu, None..
K. S. Ensbey, None..
A. E. Elz, None.
E. W. Newell,
ImmunoScape g., Board of Directors, non-salaried role), Independent Contractor, Stock, Other Business Ownership.
Neogene Therapeutics Independent Contractor.
Nanostring Technologies Independent Contractor.
Roche ).
A. Spencer, None.
G. R. Hill,
Generon Coporation Independent Contractor.
NapaJen Pharma Independent Contractor.
iTeos Therapeutics Independent Contractor, ).
Commonwealth Serum Laboratories Independent Contractor, ).
Cynata Therapeutics Independent Contractor.
Neoleukin Therapeutics Independent Contractor.
Incyte Pharma Independent Contractor, ).
Compass Therapeutics ).
Syndax Pharmaceuticals ).
Applied Molecular Transport ).
Serplus Technology ).
Heat Biologics ).
Laevoroc Oncology ).
Genentech ).